Grades and Levels of Evidence: Difference between revisions
Tyler Shultz (talk | contribs) No edit summary |
Tyler Shultz (talk | contribs) No edit summary |
||
Line 8: | Line 8: | ||
== Levels of Evidence == | == Levels of Evidence == | ||
<br> | <br> | ||
{| cellspacing="1" cellpadding="1" border="1" style="width: | {| cellspacing="1" cellpadding="1" border="1" style="width: 711px; height: 274px;" | ||
|+ Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. | |+ Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. | ||
|- | |- | ||
| '''<u>Level<br></u>''' | | '''<u>Level<br></u>''' | ||
| <u>'''Therapy/Prevetion, Aetiology/Harm'''</u>'''<br>''' | | <u>'''Therapy/Prevetion, Aetiology/Harm'''</u>'''<br>''' | ||
| <u>'''Prognosis'''</u><br> | | <u>'''Prognosis'''</u><br> | ||
| <u>'''Diagnosis'''</u><br> | | <u>'''Diagnosis'''</u><br> | ||
| <u>'''Differential Diagnosis'''</u><br> | | <u>'''Differential Diagnosis'''</u><br> | ||
| <u>'''Economic and Descision Analysis'''</u><br> | | <u>'''Economic and Descision Analysis'''</u><br> | ||
|- | |- | ||
| 1A<br> | | '''1A'''<br> | ||
| SR (with homogeneity) of RCTs <br> | | SR (with homogeneity) of RCTs <br> | ||
| SR (with homogeneity) of inception cohort studies; <br> | | SR (with homogeneity) of inception cohort studies; CDR validated in different populations<br> | ||
| SR (with homogeneity) of Level 1 diagnostic studies;<br> | | SR (with homogeneity) of Level 1 diagnostic studies; CDR with 1b studies from different clinical centres<br> | ||
| SR (with homogeneity) of prospective cohort studies <br> | | SR (with homogeneity) of prospective cohort studies <br> | ||
| SR (with homogeneity) of Level 1 economic studies<br> | | SR (with homogeneity) of Level 1 economic studies<br> | ||
|- | |- | ||
| 1B<br> | | '''1B'''<br> | ||
| <br> | | Individual RCT (with narrow Confidence Interval)<br><br> | ||
| <br> | | Individual inception cohort study with > 80% follow-up; CDR validated in a single population<br> | ||
| <br> | | Validating cohort study with good reference standards; or CDR tested within one clinical centre<br><br> | ||
| <br> | | Prospective cohort study with good follow-up<br> | ||
| <br> | | Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses<br> | ||
|- | |- | ||
| 1C<br> | | 1C<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 2A<br> | | 2A<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 2B<br> | | 2B<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 2C<br> | | 2C<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 3A<br> | | 3A<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 3B<br> | | 3B<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 4<br> | | 4<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|- | |- | ||
| 5<br> | | 5<br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
| <br> | | <br> | ||
|} | |} |
Revision as of 16:27, 8 June 2009
Original Editor - Tyler Shultz
Lead Editors - Your name will be added here if you are a lead editor on this page. Read more.
Discussion & Background[edit | edit source]
Levels of Evidence[edit | edit source]
Level |
Therapy/Prevetion, Aetiology/Harm |
Prognosis |
Diagnosis |
Differential Diagnosis |
Economic and Descision Analysis |
1A |
SR (with homogeneity) of RCTs |
SR (with homogeneity) of inception cohort studies; CDR validated in different populations |
SR (with homogeneity) of Level 1 diagnostic studies; CDR with 1b studies from different clinical centres |
SR (with homogeneity) of prospective cohort studies |
SR (with homogeneity) of Level 1 economic studies |
1B |
Individual RCT (with narrow Confidence Interval) |
Individual inception cohort study with > 80% follow-up; CDR validated in a single population |
Validating cohort study with good reference standards; or CDR tested within one clinical centre |
Prospective cohort study with good follow-up |
Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses |
1C |
|||||
2A |
|||||
2B |
|||||
2C |
|||||
3A |
|||||
3B |
|||||
4 |
|||||
5 |
Grades of Evidence[edit | edit source]
Recent Related Research (from Pubmed)[edit | edit source]
Extension:RSS -- Error: Not a valid URL: Feed goes here!!|charset=UTF-8|short|max=10
References[edit | edit source]